Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
We welcome Qualified and experienced individuals as well as Corporate from all over India to become our associates through Franchise
And we think that this is because of differences in the intrinsic efficacy of TAAR1. Talah Khoury, Slovensk akadmia vied / Slovak Academy of Sciences Our novel TAAR1/5-HT1AR dual agonist is a promising candidate for diseases characterized by psychosis and other neuropsychiatric symptoms. Masato Tanuma, Sumitomo Pharma Co., Ltd
The trajectory from $8 million in 2021 to $300 million in 2024 became a cautionary tale cited across the industry
A.SadovovaN.ZhangX.LiuS.ZouX.et al (2013)
Future perspectives Looking forward, future research should focus on several key areas to advance the therapeutic landscape for ovarian cancer: Targeted Reprogramming of TAMs: Developing more precise and effective methods to shift TAMs from the M2 to the M1 phenotype is essential
2021;23(Suppl
US$ 25.07
US$ 29.84
US$ 23.02
US$ 29.31
US$ 26.58
US$ 21.82
US$ 22.92
US$ 20.89
